

Contents

Preface V

List of Contributors XV

Abbreviations XIX

- 1 DNA Vaccines – An Overview** 1
Britta Wahren and Margaret Liu
- 1.1 Rationale for DNA Vaccines 1
1.2 Preclinical Proof of Concept 2
1.3 Clinical Trials 3
1.4 Second-Generation Vaccines 4
1.5 Conclusions 5
References 5
- 2 DNA as a Pharmaceutical – Regulatory Aspects** 7
Carsten Kneuer
- 2.1 Introduction 7
2.2 Quality Requirements for DNA used as a Gene Therapy Product 9
2.2.1 Introduction 9
2.2.2 Production and Purification 9
2.2.2.1 Raw Materials 9
2.2.2.2 Antibiotics 10
2.2.2.3 Solvents 10
2.2.2.4 Fermentation 10
2.2.2.5 Purification 11
2.2.3 Cell Banking System Procedures 11
2.2.3.1 Generation and Characterization of Master and Working Cell Banks 11
2.2.4 Product Characterization and Quality Criteria 12
2.2.4.1 Identity 13
2.2.4.2 Purity 13

DNA Pharmaceuticals: Formulation and Delivery in Gene Therapy, DNA Vaccination and Immunotherapy. Edited by Martin Schleef
Copyright © 2005 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
ISBN: 3-527-31187-4

VIII | Contents

2.2.4.3	Adventitious Agents	13
2.2.4.4	Potency	13
2.3	Safety Studies for Clinical Trials	14
2.3.1	General Considerations	14
2.3.2	Conduct of Preclinical Safety Studies	15
2.3.2.1	Regulations	15
2.3.2.2	Design of an Appropriate Toxicology Program	16
2.3.2.3	Single- and Repeat-Dose Toxicity Studies	16
2.3.2.4	Safety of the Formulated Plasmid DNA	16
2.3.2.5	Specific Safety Considerations	17
2.3.2.6	Choice of Animal Model	17
2.4	Special Issues	18
2.4.1	Comparability of Plasmid Gene Therapy Products	18
2.4.2	Mixed Plasmid Preparations	18
2.4.3	Plasmid Molecular Structure	19
2.5	Biosafety Issues and Environmental Risk Assessment	19
	<i>References</i>	20
3	From Bulk to Delivery: Plasmid Manufacturing and Storage	23
	<i>Carsten Voß, Torsten Schmidt, and Martin Schleef</i>	
3.1	Introduction	23
3.1.1	Gene Therapy	23
3.1.2	DNA Vaccination	24
3.2	Manufacturing of Plasmid DNA	24
3.2.1	Bacterial Cultivation	24
3.2.2	Plasmid DNA Purification	26
3.2.3	Innovative Aspects in Plasmid Manufacturing	28
3.3	Quality Control of Plasmid DNA Vectors	30
3.3.1	Proteins, Ribonucleic Acid, and Lipopolysaccharides	31
3.3.2	Chromosomal DNA	31
3.3.3	Plasmid Identity	32
3.3.4	Plasmid Topology (Structural Homogeneity)	32
3.4	Plasmid Stability during Storage and Application	33
3.4.1	Long-Term Stability of Plasmid DNA	33
3.4.2	Lyophilization for Long-Term Storage	36
3.4.3	Stability during Application	37
3.5	Future Developments	37
	<i>References</i>	38

4	Minimized, CpG-Depleted, and Methylated DNA Vectors: Towards Perfection in Nonviral Gene Therapy	43
	<i>Oleg Tolmachov, Richard Harbottle, Brian Bigger, and Charles Coutelle</i>	
4.1	Introduction	43
4.2	The Mammalian Immune System as a Barrier to Nonviral Gene Delivery	44
4.3	Strategies to Minimize DNA Vectors	45
4.3.1	Excision of a DNA Fragment Containing a Transgene Expression Cassette from Plasmid DNA	46
4.3.2	Intramolecular Site-Specific Recombination Within a Bacterial Plasmid	46
4.3.3	Synthesis of Minimized DNA Vectors by PCR	48
4.3.4	Improvement of Minimized DNA Vector Yield and Purity	49
4.4	Depletion of CpG Dinucleotides in the Bacterial Vector Backbone	50
4.5	Methylation of CpG Dinucleotides in Plasmid DNA	50
4.6	Towards an Ideal Nonviral Vector	51
4.7	Conclusion	52
	<i>References</i>	52
5	Localized Nucleic Acid Delivery: A Discussion of Selected Methods	55
	<i>Christian Plank, Franz Scherer, and Carsten Rudolph</i>	
5.1	Foreword	55
5.2	Nucleic Acid Delivery – What For?	55
5.3	Nucleic Acid Delivery – How?	57
5.3.1	Nucleic Acid Compaction	58
5.3.2	Receptor–Ligand Interactions	59
5.3.3	Endocytosis and Endosomal Escape	59
5.3.4	Nuclear Transport	61
5.3.5	Genome Organization	61
5.3.6	Biocompatibility	62
5.4	Why is Localization of Drug and Nucleic Acid Delivery Important?	63
5.5	Hierarchies of Localization (Targeting)	65
5.5.1	Methods of Localization and of Local Control	66
5.5.2	Nuclear Transport of Macromolecules in Living Cells	68
5.5.3	Nuclear Localization Signals and Gene Transfer	70
5.5.4	Localization Hierarchies I and II – Establishing Target Cell Contact	73
5.5.5	Vector Localization by Magnetic Force (Magnetofection)	75
5.5.6	Hydrodynamic Methods of Nucleic Acid Delivery	80
5.5.7	Local Vector Implantation. Carrier-Mediated Nucleic Acid Delivery	81
5.5.8	Injectable Implants for Localized Nucleic Acid Delivery	87
5.5.9	Aerosol Application of Nucleic Acids	88
5.5.10	Use of Ultrasound to Trigger Localized Delivery	90
5.6	Concluding Remarks	92
	<i>References</i>	93

x | Contents

6	DNA Needle Injection	117
	<i>Matthias Giese</i>	
6.1	From Mouse to Human	117
6.1.1	DNA Vaccines	117
6.1.2	Successful Strategy for Vaccination	119
6.2	Intramuscular Injection	120
6.2.1	Biology of Muscle Fibers	120
6.2.1.1	Resting Stem Cells	120
6.2.2	Uptake of Plasmid DNA	121
6.2.3	Activation of the Immune System	121
6.2.3.1	Receptors and other Signals	122
6.2.3.2	Antigen Presentation	122
6.2.4	Cross-Priming	123
6.2.5	Safety Aspects	124
6.2.5.1	Uptake of the DNA by Muscle Cells	124
6.2.5.2	Antigen Processing	124
6.2.5.3	Antigen Presentation	125
6.2.6	DNA Vaccination of Horses against Infection with Equine Arteritis Virus I	126
6.3	Intradermal Injection	128
6.3.1	Skin-Associated Lymphoid Tissue (SALT)	128
6.3.2	DNA Vaccination of Horses Against Infection with Equine Arteritis Virus II	129
6.4	Concluding Remarks	131
	<i>References</i>	131
7	Needleless Jet Injection of Naked DNA for Nonviral in vivo Gene Transfer	133
	<i>Wolfgang Walther and Ulrike Stein</i>	
7.1	Introduction	133
7.2	In vivo Application of Jet Injection	136
7.2.1	Intratumoral Jet Injection of Naked Plasmid DNA	136
7.2.2	Analysis of Reporter Gene Expression in Jet-Injected Tumors	137
7.2.3	Analysis of the Stability of Jet-Injected Naked DNA	138
7.3	Conclusions	139
	<i>References</i>	140
8	Plasmid Inhalation: Delivery to the Airways	145
	<i>Lee A. Davies, Stephen C. Hyde, and Deborah R. Gill</i>	
8.1	Introduction	145
8.2	Delivery Methods	146
8.2.1	Lung Delivery by Instillation	146
8.2.2	Delivery by Aerosol	147

8.2.3	Aerosol Deposition	148
8.2.4	Aerosolization Devices	148
8.2.4.1	Metered Dose Inhalers	149
8.2.4.2	Dry Powder Inhalers	150
8.2.4.3	Nebulizers	150
8.2.5	Aerosolization of Plasmid DNA	152
8.2.6	Plasmid DNA/Lipid Complexes	153
8.2.6.1	Optimization of Aerosol Formulation	153
8.2.6.2	Aerosol Delivery of Lipid/pDNA to Human Lung	154
8.2.7	Plasmid Delivery with Cationic Polymers	155
8.3	Future Directions	157
8.4	Conclusions	158
	<i>References</i>	159
9	Hydrodynamic Gene Delivery	165
	<i>John W. Fabre</i>	
9.1	Definition	165
9.2	Initial Discovery of the Technique	165
9.3	The Systemic Hydrodynamic Approach	166
9.4	The Regional Hydrodynamic Approach to the Liver	167
9.5	Gene Delivery to the Liver in Large Animals	167
9.6	Hydrodynamic Gene Delivery to Tissues other than Liver	168
9.6.1	Skeletal Muscle	168
9.6.2	Kidney	169
9.7	Mechanisms of Gene Delivery	170
9.8	Safety and Clinical Applicability	170
	<i>References</i>	171
10	DNA Pharmaceuticals for Skin Diseases	173
	<i>Vitali Alexeev and Jouni Uitto</i>	
10.1	Introduction	173
10.2	Recombinant DNA-Based Skin Gene Therapy	174
10.2.1	Correction of Genetic Disorders	174
10.2.2	“Suicide” Gene Therapy	176
10.2.3	Genetic Pharmacology	176
10.3	DNA Vaccines	176
10.3.1	DNA Vaccination Through Skin	178
10.3.2	DNA Vaccines Against Skin Cancers	179
10.4	Physical Methods of DNA Delivery	180
10.4.1	Delivery of DNA to the Skin by Particle Bombardment	181
10.4.2	Microparticles for DNA Delivery	182
10.4.3	Genetic Immunization by Jet Injection	182
10.4.4	Epidermal Powder Immunization	183
	<i>References</i>	184

XII | Contents

11	Electrotransfection – An Overview	189
	<i>Capucine Trollet, Pascal Bigey, and Daniel Scherman</i>	
11.1	Theory and Mechanisms	190
11.1.1	History	190
11.1.2	Mechanism of in vitro Electrotransfection at the Scale of a Single Cell	190
11.1.2.1	Permeabilization	190
11.1.2.2	Uptake of DNA	192
11.1.3	Mechanism of in vivo DNA Electrotransfer	192
11.2	In vivo DNA Electrotransfer in Practice	194
11.2.1	Device and Electrical Parameters	195
11.2.2	DNA Electrotransfer and Toxicity	197
11.2.3	Plasmid Biodistribution	197
11.3	Targeted Tissues	199
11.3.1	Skeletal Muscle	199
11.3.2	Tumor Tissue	200
11.3.3	Skin	201
11.3.4	Liver	201
11.3.5	Lung	202
11.3.6	Vasculature	202
11.3.7	Eye	202
11.3.8	Embryos	203
11.3.9	Cartilage	203
11.3.10	Gonads	203
11.4	Therapeutic Applications	204
11.4.1	Intramuscular Electrotransfer	204
11.4.1.1	Ectopic Secretion of Proteins	204
11.4.1.2	Muscle Disease Therapy	205
11.4.2	Vaccination	205
11.4.3	Cancer Gene Therapy	206
11.4.3.1	Strengthening Antitumor Response	207
11.4.3.2	Suicide Genes	207
11.4.3.3	Apoptosis-Inducing Genes	207
11.4.3.4	Inhibition of Tumor Angiogenesis	208
11.4.3.5	Other Strategies	208
11.4.4	Electrotransfer as a Tool	208
11.5	Conclusion	209
	<i>References</i>	210

12	Electrogenettransfer in Clinical Applications	219
	<i>Lluís M. Mir</i>	
12.1	Summary of the Basis of Electrogenetherapy	219
12.1.1	Tissue Electroporpermabilization	219
12.1.2	DNA Electrophoresis	220
12.1.3	The Interest of Electrogenetherapy	220
12.2	The Road to Clinical Electrogenetherapy	221
12.2.1	Basic Difficulties and Requirements	221
12.2.1.1	Electrogenetherapy is a Local Treatment	221
12.2.1.2	DNA Injection	222
12.2.1.3	Need for Appropriate Electrodes	222
12.2.1.4	Need for Appropriate Electrical Pulse Generators	222
12.2.1.5	Electrogenetherapy and Public and Professional Perceptions of the Biomedical Use of Electricity	222
12.2.2	The Cliniporator Project	223
12.2.3	The ESOPÉ Project	223
12.2.4	Future Perspectives	224
	<i>References</i>	225
13	Cancer Inhibition in Mice After Systemic Application of Plasmid-Driven Expression of Small Interfering RNAs	227
	<i>Birgit Spänkuch and Klaus Strebhardt</i>	
13.1	Introduction	227
13.2	Plasmid-Expressed siRNA	228
13.2.1	PLK1 shRNA-Mediated Inhibition of PLK1 Expression	228
13.2.2	Nuclease Inhibitor ATA and Stability of Plasmid DNA in Mammalian Blood	230
13.2.3	Antitumor Activity of PLK1 shRNA in vivo	232
13.2.4	Vector-Induced Decreased Expression of PLK1 and Antitumor Activity	234
13.3	Conclusion and Future Directions	237
	<i>References</i>	238
	Subject Index	241



List of Contributors

Vitali Alexeev

Department of Dermatology and
Cutaneous Biology
Jefferson Medical College
233 South 10th Street
Suite 326 BLSB
Philadelphia, PA 19107
USA

Pascal Bigey

Laboratoire de Pharmacologie
Chimique et Génétique
INSERM U640 – CNRS UMR8151
Université René Descartes – ENSCP
Faculté de Pharmacie
4, Avenue de l'Observatoire
75270 Paris Cédex 06
France

Brian Bigger

Stem Cell Research Group
John Radcliffe Hospital
University of Oxford
Oxford OX3 9BQ
United Kingdom

Charles Coutelle

Gene Therapy Research Group
Imperial College
Exhibition Road
London SW7 2AZ
United Kingdom

Lee A. Davies

Gene Medicine Group
John Radcliffe Hospital
University of Oxford
Oxford OX3 9DU
United Kingdom

John Fabre

Department of Clinical Science
The Rayne Institute
Guy's, King's and St. Thomas' School
of Medicine
123 Coldharbour Lane
London SE5 9NU
United Kingdom

Matthias Giese

Im Schaffner 24
69123 Heidelberg
Germany

Deborah Gill

Gene Medicine Group
John Radcliffe Hospital
University of Oxford
Oxford OX3 9DU
United Kingdom

Richard Harbottle

Gene Therapy Research Group
Imperial College
Exhibition Road
London SW7 2AZ
United Kingdom

*DNA Pharmaceuticals: Formulation and Delivery in Gene Therapy,
DNA Vaccination and Immunotherapy.* Edited by Martin Schleef
Copyright © 2005 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
ISBN: 3-527-31187-4

Stephen C. Hyde

Gene Medicine Group
John Radcliffe Hospital
University of Oxford
Oxford OX3 9DU
United Kingdom

Carsten Kneuer

Institute for Pharmacology,
Pharmacy and Toxicology
University of Leipzig
An den Tierkliniken 15
04103 Leipzig
Germany

Margaret Liu

3656 Happy Valley Road
Lafayette, CA 94549
USA
and
11, Rue de Molsheim
67082 Strasbourg
France

Lluis M. Mir

Laboratory of Vectorology and
Gene Transfer
UMR 8121 CNRS –
Institut Gustave-Roussy
39, Rue C. Desmoulins
94805 Villejuif Cédex
France

Christian Plank

Department for Experimental
Oncology (IEOT)
Munich Technical University
Ismaninger Strasse 22
81675 Munich
Germany

Carsten Rudolph

Department of Molecular Pneumology
Dr. von Hauner Children's Hospital
Ludwig-Maximilians-University
Lindwurmstrasse 4
80337 Munich
Germany

Franz Scherer

Department for Experimental
Oncology (IEOT)
Munich Technical University
Ismaninger Strasse 22
81675 Munich
Germany

Daniel Scherman

Chemical and Genetic Pharmacology
INSERM U266 – CNRS FRE 2463
Université René Descartes
4, Avenue de l'Observatoire
75270 Paris Cédex 06
France

Martin Schleef

PlasmidFactory GmbH & Co. KG
Meisenstrasse 96
33607 Bielefeld
Germany

Torsten Schmidt

PlasmidFactory GmbH & Co. KG
Meisenstrasse 96
33607 Bielefeld
Germany

Birgit Spänkuch

Department of Gynecology and
Obstetrics
School of Medicine
University of Frankfurt
Theodor-Stern-Kai 7
60590 Frankfurt
Germany

Ulrike Stein

Max-Delbrück-Center for Molecular
Medicine
Robert-Rössle-Strasse 10
13092 Berlin
Germany

Klaus Strebhardt

Department of Gynecology and
Obstetrics
School of Medicine
University of Frankfurt
Theodor-Stern-Kai 7
60590 Frankfurt
Germany

Oleg Tolmachov

Gene Therapy Research Group
Imperial College
Exhibition Road
London SW7 2AZ
United Kingdom

Capucine Trollet

Chemical and Genetic Pharmacology
INSERM U640 – CNRS UMR 8151
Université René Descartes
4, Avenue de l'Observatoire
75270 Paris Cédex 06
France

Jouni Uitto

Department of Dermatology and
Cutaneous Biology
Jefferson Institute of Molecular
Medicine
233 South 10th Street, Suite 450
Philadelphia, PA 19107
USA

Carsten Voß

Technology Department
University of Bielefeld
Universitätsstrasse 25
33615 Bielefeld
Germany

Britta Wahren

Department of Virology
Swedish Institute for Infectious
Disease Control
Karolinska Institute
17182 Solna
Sweden

Wolfgang Walther

Max-Delbrück-Center for Molecular
Medicine
Robert-Rössle-Strasse 10
13092 Berlin
Germany

